• ACADIA Pharmaceuticals posted Q2 GAAP total revenues of USD 308 million, up 16% year over year; net income rose to USD 32 million.
• GAAP net sales climbed to USD 183 million for NUPLAZID, up 9% year over year; DAYBUE net sales rose to USD 125 million, up 30%.
• R&D expense increased to USD 82 million; SG&A expense climbed to USD 160 million.
• Cash, cash equivalents and investment securities totaled USD 956 million at June 30, 2026.
• Raised full-year 2026 GAAP total revenue guidance to USD 1.24 billion-USD 1.3 billion; cut R&D expense outlook to USD 355 million-USD 380 million.
• Phase 2 remlifanserin topline results in Alzheimer’s disease psychosis expected in September to October 2026; FDA granted Fast Track designation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608041605BIZWIRE_USPR_____20260804_BW047448) on August 04, 2026, and is solely responsible for the information contained therein.